LUBBOCK, Texas – Gov. Greg Abbott will travel to Lubbock on Thursday to hold a briefing with local officials and provide an update on the distribution of Bamlanivimab, the Eli Lilly & Company monoclonal antibody therapy for COVID-19.
The governor will be joined by Texas Department of State Health Services (DSHS) Commissioner John Hellerstedt, MD, Texas Division of Emergency Management (TDEM) Chief Nim Kidd, and University of Texas (UT) System Executive Vice Chancellor of Health Affairs John Zerwas, MD.
Abbott said Friday that the Texas Department of State Health Services will distribute the therapy Bamlanivimab to hospitals across Texas.
Bamlanivimab is for outpatient use in people who have tested positive for COVID-19 and are at increased risk of severe disease. It has been shown to prevent hospitalizations in some patients when used before they become very sick.
These weekly shipments of doses have been provided to the state at no cost through the U.S. Department of Health and Human Services, according to Abbott’s office.
Abbott’s office said DSHS will allocate this initial distribution of Bamlanivimab based on three criteria: new confirmed cases of COVID-19 in the community, new lab-confirmed COVID-19 admissions to hospitals, and total lab-confirmed COVID-19 patients in hospitals.
“This initial allotment of Bamlanivimab will help health care professionals effectively treat cases of COVID-19 within their communities and aid in reducing hospitalizations,” Abbott is quoted as saying in a news release. “I thank the U.S. Department of Health and Human Services for providing Texas with this crucial antibody therapy that will help keep Texans safe and mitigate the spread of COVID-19.”
Copyright 2020 by KPRC Click2Houston – All rights reserved.